<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809106</url>
  </required_header>
  <id_info>
    <org_study_id>Studio CERP</org_study_id>
    <nct_id>NCT01809106</nct_id>
  </id_info>
  <brief_title>RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.</brief_title>
  <acronym>CERP</acronym>
  <official_title>RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain, in neoplastic disease, is a symptom with severe negative impact on the quality of life
      of patients and a high incidence, with values around 70-90% in advanced and metastatic
      stages. Than 20 years the main reference for the pharmacological treatment of cancer pain are
      the guidelines produced by the World Health Organization (WHO). This document shows that the
      use of opioid drugs is the mainstay of treatment, with particular reference to opioids
      &quot;major&quot; (3 rd step of the analgesic ladder). The 4 opioids more most commonly prescribed in
      Italy (oral morphine and oxycodone, fentanyl and buprenorphine transdermal), based on the
      data currently available, have an analgesic effect would partly overlap but with different
      percentages of non-responders (NR), a different need to increase the dose over time to
      maintain adequate analgesia, a different action to the switch to another molecule for
      ineffectiveness analgesic. The observations described suggest that opioids, although they
      belong to the same family drug may not be fully comparable with regard to the clinical
      effects products. Important differences are known on the pharmacokinetic and pharmacodynamic
      and, more recently, also in terms of pharmacogenomics. This is a comparative study of
      analgesic strategies based on the use of the 4 mentioned opioids, going to look for possible
      differences in terms of analgesic efficacy, changes in dose over time, use of switch or
      permanent abandonment of treatment, parallel to the contour of the side effects. The
      associated sub-project will link the structure gene of patients and clinical results have
      emerged.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Non-Responder (NR) Participants</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of the proportion of Non-Responder (NR) participants. NR correspond to the subjects who do not report any analgesic effects, with a P.I.D. (pain intensity difference) from visit 6 and visit 1 =/&lt; 0%, (using a 0-10 NRS ). It includes the situations of average pain intensity &quot;stable&quot; or &quot;worsened&quot; at day 28 compared with baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Full-responder</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of the proportion of subjects who report full analgesia (full responders: FR). FR is operationally defined as a patient with a P.I.D. =/&gt; 30% from visit 6 and visit 1 (NRS 0 to 10).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Opioid Escalation Index</measure>
    <time_frame>28 days</time_frame>
    <description>The proportion of subjects with an increase of opioid daily dose &gt; 5% compared with the basal dosage (OEI%).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">518</enrollment>
  <condition>Cancer</condition>
  <condition>Cancer Pain</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>60 mg /24 ore</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>25 microg/h</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>35 microg/h</description>
    <arm_group_label>Buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>40 mg /24 ore</description>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnostic (histological or cytological) evidence of locally advanced or
             metastatic solid tumour;

          -  with average pain intensity ≥ 4, measured with NRS and related to the last 24 hours,
             due to the cancer, requiring for the first time an analgesic treatment with 3rd
             step/WHO opioids

          -  with life expectancy &gt; one month

          -  &quot;strong&quot; opioid naïve;

          -  eligible to take any of the medications under evaluation, by TDS or by mouth;

          -  with age ≥ 18 years;

        Exclusion Criteria:

          -  Patients recruited in other researches that conflict or may confound the conduction
             and results of the present study;

          -  Lack of informed consent;

          -  with presence of other diseases, including psychiatric/mental illness, severe senile
             or other form of dementia, that can interfere with participation and compliance with
             the study protocol or can contraindicate the use of the investigational drugs;

          -  with presence of co-morbidities, which could create potentially dangerous drug
             interactions with opioids (eg, use of macrolide antibiotics or antifungal,….);

          -  any kind of contraindications to the use of opioid drugs;

          -  Patients with a known story, past or current, of drugs abuse or addiction;

          -  Use of drugs which presents a combination of opioids and other molecule (as NSAIDs,
             paracetamol, naloxone, ..);

          -  Patients who cannot guarantee regular follow-up visits for logistic or geographic
             reasons;

          -  Need of starting 3rd step treatment in an &quot;emergency clinical situation&quot; that do not
             allow the correct procedures of randomization;

          -  diagnosis of primary brain tumor or leukaemia;

          -  diagnosis of chronic renal failure;

          -  patients with antalgic radiotherapy or radio-metabolic therapy in progress or
             completed less than 14 days before study;

          -  patients starting a first line chemotherapy simultaneously to the beginning of the
             study;

          -  other types of analgesic treatments, including local-regional anesthetic techniques or
             neurosurgical /ablative methods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Corli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute of Pharmacological Research - IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova Azienda Ospedaliera</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Marta</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Valtellina-Valchiavenna</name>
      <address>
        <city>Morbegno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Battista di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Gradenigo</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://crc.marionegri.it/cancerpain/</url>
    <description>Info of the study</description>
  </link>
  <reference>
    <citation>Apolone G, Bertetto O, Caraceni A, Corli O, De Conno F, Labianca R, Maltoni M, Nicora M, Torri V, Zucco F; Cancer Pain Outcome Research Study Group. Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health Qual Life Outcomes. 2006 Feb 2;4:7.</citation>
    <PMID>16457716</PMID>
  </reference>
  <reference>
    <citation>Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009 May 19;100(10):1566-74. doi: 10.1038/sj.bjc.6605053. Epub 2009 Apr 28.</citation>
    <PMID>19401688</PMID>
  </reference>
  <reference>
    <citation>Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G; Writing Protocol Committee; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011 Jan;27(1):9-18. doi: 10.1097/AJP.0b013e3181edc250.</citation>
    <PMID>20842024</PMID>
  </reference>
  <reference>
    <citation>Apolone G, Deandrea S, Montanari M, Corli O, Greco MT, Cavuto S. Evaluation of the comparative analgesic effectiveness of transdermal and oral opioids in cancer patients: a propensity score analysis. Eur J Pain. 2012 Feb;16(2):229-38. doi: 10.1002/j.1532-2149.2011.00020.x. Epub 2011 Dec 19.</citation>
    <PMID>22323375</PMID>
  </reference>
  <reference>
    <citation>Corli O, Montanari M, Deandrea S, Greco MT, Villani W, Apolone G. An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. Pain Med. 2012 Jul;13(7):897-907. doi: 10.1111/j.1526-4637.2012.01408.x. Epub 2012 Jun 8.</citation>
    <PMID>22680789</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2013</study_first_posted>
  <results_first_submitted>October 20, 2015</results_first_submitted>
  <results_first_submitted_qc>October 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2015</results_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer pain</keyword>
  <keyword>major opioid</keyword>
  <keyword>analgesics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of First Enrollment: May 2014 Date of last enrollment: July 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Morphine</title>
          <description>Morphine: 60 mg /24 ore</description>
        </group>
        <group group_id="P2">
          <title>Oxycodone</title>
          <description>Oxycodone: 40 mg /24 ore</description>
        </group>
        <group group_id="P3">
          <title>Buprenorphine</title>
          <description>Buprenorphine: 35 microg/h</description>
        </group>
        <group group_id="P4">
          <title>Fentanyl</title>
          <description>Fentanyl: 25 microg/h</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="130"/>
                <participants group_id="P4" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Morphine</title>
          <description>Morphine: 60 mg /24 ore</description>
        </group>
        <group group_id="B2">
          <title>Oxycodone</title>
          <description>Oxycodone: 40 mg /24 ore</description>
        </group>
        <group group_id="B3">
          <title>Buprenorphine</title>
          <description>Buprenorphine: 35 microg/h</description>
        </group>
        <group group_id="B4">
          <title>Fentanyl</title>
          <description>Fentanyl: 25 microg/h</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="127"/>
            <count group_id="B4" value="124"/>
            <count group_id="B5" value="498"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="11.7"/>
                    <measurement group_id="B2" value="66.9" spread="11.1"/>
                    <measurement group_id="B3" value="65.2" spread="13.5"/>
                    <measurement group_id="B4" value="68" spread="10.6"/>
                    <measurement group_id="B5" value="66.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Non-Responder (NR) Participants</title>
        <description>Evaluation of the proportion of Non-Responder (NR) participants. NR correspond to the subjects who do not report any analgesic effects, with a P.I.D. (pain intensity difference) from visit 6 and visit 1 =/&lt; 0%, (using a 0-10 NRS ). It includes the situations of average pain intensity “stable” or “worsened” at day 28 compared with baseline values.</description>
        <time_frame>28 days</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>Morphine: 60 mg /24 ore</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>Oxycodone: 40 mg /24 ore</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine</title>
            <description>Buprenorphine: 35 microg/h</description>
          </group>
          <group group_id="O4">
            <title>Fentanyl</title>
            <description>Fentanyl: 25 microg/h</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Non-Responder (NR) Participants</title>
          <description>Evaluation of the proportion of Non-Responder (NR) participants. NR correspond to the subjects who do not report any analgesic effects, with a P.I.D. (pain intensity difference) from visit 6 and visit 1 =/&lt; 0%, (using a 0-10 NRS ). It includes the situations of average pain intensity “stable” or “worsened” at day 28 compared with baseline values.</description>
          <population>Intention-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Full-responder</title>
        <description>Evaluation of the proportion of subjects who report full analgesia (full responders: FR). FR is operationally defined as a patient with a P.I.D. =/&gt; 30% from visit 6 and visit 1 (NRS 0 to 10).</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>Morphine: 60 mg /24 ore</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>Oxycodone: 40 mg /24 ore</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine</title>
            <description>Buprenorphine: 35 microg/h</description>
          </group>
          <group group_id="O4">
            <title>Fentanyl</title>
            <description>Fentanyl: 25 microg/h</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Full-responder</title>
          <description>Evaluation of the proportion of subjects who report full analgesia (full responders: FR). FR is operationally defined as a patient with a P.I.D. =/&gt; 30% from visit 6 and visit 1 (NRS 0 to 10).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Opioid Escalation Index</title>
        <description>The proportion of subjects with an increase of opioid daily dose &gt; 5% compared with the basal dosage (OEI%).</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>Morphine: 60 mg /24 ore</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>Oxycodone: 40 mg /24 ore</description>
          </group>
          <group group_id="O3">
            <title>Buprenorphine</title>
            <description>Buprenorphine: 35 microg/h</description>
          </group>
          <group group_id="O4">
            <title>Fentanyl</title>
            <description>Fentanyl: 25 microg/h</description>
          </group>
        </group_list>
        <measure>
          <title>The Opioid Escalation Index</title>
          <description>The proportion of subjects with an increase of opioid daily dose &gt; 5% compared with the basal dosage (OEI%).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Morphine</title>
          <description>Morphine: 60 mg /24 ore</description>
        </group>
        <group group_id="E2">
          <title>Oxycodone</title>
          <description>Oxycodone: 40 mg /24 ore</description>
        </group>
        <group group_id="E3">
          <title>Buprenorphine</title>
          <description>Buprenorphine: 35 microg/h</description>
        </group>
        <group group_id="E4">
          <title>Fentanyl</title>
          <description>Fentanyl: 25 microg/h</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bowel occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>oral cavity bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>exitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>decline general condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>hyperpyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>hyperalgesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="79" subjects_affected="79" subjects_at_risk="122"/>
                <counts group_id="E2" events="74" subjects_affected="74" subjects_at_risk="125"/>
                <counts group_id="E3" events="81" subjects_affected="81" subjects_at_risk="127"/>
                <counts group_id="E4" events="70" subjects_affected="70" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="122"/>
                <counts group_id="E2" events="55" subjects_affected="55" subjects_at_risk="125"/>
                <counts group_id="E3" events="61" subjects_affected="61" subjects_at_risk="127"/>
                <counts group_id="E4" events="46" subjects_affected="46" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Oscar Corli</name_or_title>
      <organization>Mario Negri Institution</organization>
      <phone>+390239014564</phone>
      <email>oscar.corli@marionegri.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

